Aubuchon Neil William — SEC Form 4 filings
SEC reporting owner CIK 2106781. 2 Form 4 filings on record with FilingPulse; latest filed 2026-03-10.
Transaction summary — filings shown
Covers all 2 filings on record, filed 2026-01-26 to 2026-03-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 4,475 shares, $149,912 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: purchase of 4,475 shares @ $33.50 ($149,912) in Viking Therapeutics, Inc., filed 2026-03-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | Chief Commercial Officer | 2 | 1 leg · 4,475 sh · $149,912 | — | 1 |
Form 4 filings — Aubuchon Neil William
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-10 | 4 | Viking Therapeutics, Inc. (VKTX) | Purchase (P): 4,475 @ $33.50 | EDGAR |
| 2026-01-26 | 4 | Viking Therapeutics, Inc. (VKTX) | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=2106781 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →